PCSK9 and atherosclerosis: As an add-on-statin therapy, proprotein convertase subtilsin/kexin type 9 (PCSK9) inhibitors (PCSK9i) have shown powerful effect on lowering LDL as well as ASCVD events (Cannon et al., 2015; Chaudhary et al., 2017).